Our News


Business Development and Licensing Select Deal Highlights

We are active in dealmaking worldwide.

MERGERS & ACQUISITIONS:

June 2019   Acquisition of Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.
May 2019   Acquisition of Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate is PT2977, a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma (RCC).
February 2019   Acquisition of Immune Design, a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's proprietary technologies, GLAAS® and ZVex®, are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases.
February 2018   Acquisition of Viralytics, a company focused on oncolytic immunotherapy treatments for a range of cancers including CAVATAK® (CVA21), an investigational oncolytic immunotherapy that has been shown to preferentially infect and kill cancer cells.
September 2017   Acquisition of Rigontec, a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec’s lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors.

RESEARCH COLLABORATIONS & LICENSES:

August 2019   Harvard University collaboration to discover novel aspects of the immune system that may be targeted in future treatments for cancer.
July 2019   Collaboration agreement with Skyhawk Therapeutics, to discover, develop and commercialize small molecules that modulate RNA splicing. Skyhawk's proprietary SkySTAR™ technology platform will be employed to discover and develop innovative RNA-binding small molecules designed to selectively modify RNA splicing, as a new modality for the potential treatment of certain neurological diseases and cancer.
March 2019   Collaboration and license deal with King’s College London and Wellcome  focused on developing solutions for chronic pain, an area of huge unmet clinical need.
January 2019   The company exercised its option to license NGM’s NGM313,  an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and type 2.
January 2019   License and collaboration agreement with Cocrystal Pharma  to discover and develop certain proprietary influenza A/B antiviral agents.
January 2019   Licensing agreement with Amunix for rights to develop therapeutics  against an undisclosed target using Amunix’s proprietary protease-triggered immune activator (ProTIA) technology platform.
December 2018   Collaboration agreement with Instituto Butantan  to develop vaccines to protect against dengue virus disease, the mosquito-borne infection. Instituto Butantan’s dengue vaccine candidate, TV003, is currently being evaluated in a large Phase 3 study in Brazil.
October 2018   Licensing collaboration for use of ImaginAb’s novel minibody  CD8 T Cell imaging agent in immuno-oncology clinical trials for multiple types of cancers. In addition, We are making an equity investment in ImaginAb’s Series B round of financing.
October 2018   Collaboration with Dragonfly  to discover, develop and commercialize immunotherapies for patients with solid tumor cancers using Dragonfly’s TriNKET™ technology platform.
July 2018   Expansion of the collaboration with HitGen  to build and screen novel DNA-encoded libraries to discover potential unique small molecule assets to be used in drug discovery and development.
July 2018   Collaboration with Sutro  to leverage its proprietary platforms to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders.
June 2018   Licensing agreement with PeptiDream  for use of its Peptide Discovery Platform System (PDPS) technology. PeptiDream will continue to work with us to identify macrocyclic/ constrained peptides against multiple targets of interest and to optimize hit peptides into therapeutic peptides or small molecule products under a prior agreement.
May 2018   Collaboration with Foundation Medicine  to develop companion diagnostic tests for use with KEYTRUDA® (pembrolizumab), Our anti-PD-1 therapy and the fi rst approved immunotherapy for microsatellite instability (MSI) high or mismatch repair deficient solid tumors.
May 2018   Expansion of collaboration with Moderna  to develop and commercialize novel personalized mRNA cancer vaccines to include shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine.
March 2018   Collaboration with Eisai  to jointly develop and commercialize its LENVIMA® (lenvatinibmesylate), an orally available tyrosine kinase inhibitor, as monotherapy and in combination with our anti-PD-1 therapy KEYTRUDA® (pembrolizumab).
December 2017   Global research project with FinnGen  focusing on use of genome data in search of the next breakthroughs in disease prevention, diagnosis and treatment.
November 2017   Collaboration with Cue Biopharma  to apply CUE Biologics™ platform to develop biologics disease.
October 2017   Collaboration agreement with KalVista  for KVD001 an investigational intravitreal injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition.
July 2017   Collaboration with AstraZeneca  to co-develop and co-commercialize AstraZeneca’s LYNPARZA (olaparib) — an oral poly ADP ribose polymerase (PARP) inhibitor — for multiple cancer types. Additionally, companies will jointly develop and commercialize AstraZeneca’s selumetinib, an oral, potent, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, being developed for multiple indications including thyroid cancer.
June 2017   Collaboration to apply SerImmune’s  immune repertoire characterization platform to clinical and preclinical specimens to advance efforts in infectious diseases.
May 2017   Licensing agreement with Teijin  for an investigational preclinical antibody candidate targeting the protein tau. Changes in tau are associated with a number of diseases affecting the nervous system, including Alzheimer’s disease.
March 2017   Collaboration with HitGen  to discover novel chemical leads for multiple therapeutic targets using HitGen’s core technology platform, based on DNA-encoded library design, synthesis and screening.
March 2017   Investment in Series B financing with Grail  to develop blood tests for early detection of cancer.
March 2017   Agreement with CDRD / McGill University  to create a novel drug development platform to help advance new therapeutics for debilitating conditions such as amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and Parkinson’s disease.
January 2017   Licensing agreement with Cerveau Technologies  for the commercialization of MK-6240 for use in PET scans to image neurofi brillary tangles in the brain.

KEYTRUDA COMBINATIONS:

We have a long list of partnerships and continue to seek collaborations in the immuno-oncology space.